Paul Viscuse, MD

Genitourinary Oncologist at University of Virginia. Opinions are my own.

[Andy Hahn @OncHahn]

Check out our editorial on CV risk in men with prostate cancer treated with ADT https://t.co/Vy9hwbddRJ @pcan_journal We discuss the need to develop risk models specific to men with PCa and to better understand the biologic determinants of toxicity @aaparicioMD @MDAndersonNews

[Andy Hahn @OncHahn]

Check out our review on AR in non-cancer cells, https://t.co/HNjkyTxITR, including the immune system, fibroblasts, bone, adipocytes and CV in @TheEndoSociety Learned a lot from co-authors on the complicated role of AR signaling in these compartments. @DanielFrigo led this effort!

[Firas El Chaer, MD, MSHCM @FirasElChaer]

I am honored & humbled to receive this year’s @UvaDOM GME excellence in mentorship award. I’m privileged to pay forward the guidance & support of my own best mentors @ChemalyRoy @DrChrisHourigan @Dr_AmerZeidan @JeffAuletta @page_md @UVACancerCenter @uvaimr @uvahealthnews

[Andy Hahn @OncHahn]

The disease volume analysis of ARASENS is inconclusive for tx effect heterogeneity. There is significant uncertainty for low volume men given the low numbers. Questions remains for the utility of adding docetaxel to ADT + ASI #GU23

[Paul Viscuse, MD @PViscuse]

Excellent presentation of impressive and important work by my @uvahealthnews @UVACancerCenter colleague Dr. Ibilibor illustrating factors contributing to #urothelialcancer disparities by race/gender and offers framework for more equitable guideline-based care. #GU23

[Paul Viscuse, MD @PViscuse]

Impressive data presented from well designed TRITON3 trial of rucaparib in mCRPC BY @AlanBryce9. Will be my PARP of choice in BRCA+. Concerning that physicians still gave second ARSI over docetaxel despite known inferiority, need to emphasize chemo. #guasco #prostatecancer

[Paul Viscuse, MD @PViscuse]

Had great experience at the @ASCO @ConquerCancerFd retreat receiving invaluable early career advice while learning about impressive research conducted by other early career oncologists around the world. And of course reuniting with @OncHahn

[UroToday.com @urotoday]

A phase II study of lenvatinib + everolimus vs cabozantinib in pts with #mRCC that progressed on a PD-1/PD-L1 checkpoint inhibitor (LenCabo). Presented by @OncHahn @MDAndersonNews. #IKCSNA22 written coverage by @WallisCJD @UofT > https://t.co/dGxJ5SFyoL @KidneyCancer

[Cancers MDPI @Cancers_MDPI]

🔆This #Article using 28 PDX models links loss-of-function transcriptional scores to NGS & IHC alterations in TP53, RB1 & PTEN to inform clinical use of the #AVPC molecular profile🔆

👥by @RamaS_PhD, @PViscuse, @aaparicioMD et al.

Enjoy reading➡️https://t.co/RXoEFNxVwZ

[Paul Viscuse, MD @PViscuse]

Very exciting OS data from the #ATOMIC study with ADI-PEG20 plus platinum chemotherapy in pleural #mesothelioma. Hoping to have similar success with our work studying ADI-PEG20 with platinum chemotherapy in the aggressive variant #ProstateCancer

https://t.co/WJSD1sVfDw

[Pavlos Msaouel @PavlosMsaouel]

If presenting or interpreting forest plots from RCTs #ESMO2022, make sure to include the main effect & draw a vertical line corresponding to its point estimate. Treatment homogeneity can also be assessed by the indifference zone approach 👉 https://t.co/I2AyH7oLLD

[Enrique Grande @drenriquegrande]

Wonderful graph by @shilpaonc and cols. at
https://t.co/mSO8OSSMQh
showing crystal clear the differences in the profile of patients with #urothelial carcinoma recruited in large clinical trials vs real-practice. I'm wondering if we can really extrapolate the data? @OncoAlert

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking news: @US_FDA approves darolutamide (Nubeqa) for metastatic castration sensitive #prostatecancer in combination with docetaxel based on the results of ph3 Arasens trial👇 @PCF_Science @OncoAlert @urotoday https://t.co/hsJ005pHjE

[Tom Powles @tompowles1]

6 months of adjuvant ipi/nivo did not improve DFS in renal cancer. This is in contrast adjuvant pembro. It’s hard to see on face value why these results would be different. Duration of therapy, blinded radiology review and tolerably are considerations. https://t.co/7oYBMWpIoq

[Andy Hahn @OncHahn]

Great experience learning and presenting at the Energy Balance Retreat @MDAndersonNews. Accounting for host factors is critical for patients with GU cancers and beyond. Insightful keynote by @LocasaleLab

[Nima Sharifi @NimaSharifiMD]

Many assume that because vitamins or supplements are natural they can’t do harm. Here is a large trial showing INCREASED death with Vit C in patients with sepsis - showing again the no harm assumption is false. You have to generate evidence. ⁦@NEJM⁩ https://t.co/JUldtluAAn

[Paul Viscuse, MD @PViscuse]

Had wonderful @MDAndersonNews graduation and am thankful to mentors @aaparicioMD @DanielFrigo @AmishiYShah #NizarTannir for being a part of it. Also honored to be awarded the Richard Theriault Humanitas Award. Looking forward to next step at @uvahealthnews @UVACancerCenter

[Pavlos Msaouel @PavlosMsaouel]

@neerajaiims @SWOG @PrimoLaraMD @DrChoueiri @KCA_Journal @TiansterZhang @shilpaonc @montypal @crisbergerot @ADesaiMD @VivekSubbiah @NazliDizman ☝️I would be curious to hear what the @SWOG statisticians think of this forest plot. @f2harrell @ESteyerberg @pash22 @OAlhalabiMD @OncHahn @NazliDizman @PViscuse @d_shapiro1 @DrMBWesterman

[Paul Viscuse, MD @PViscuse]

Great presentation by Dr. Krupski from @uvaurology at #ASCO22 highlighting the lack of available local urologists in many US counties and the feasibility of tele-cystoscopy as one method to address barriers to care and #healthequity.

[Paul Viscuse, MD @PViscuse]

Enjoyed sharing the final outcomes data of the DynAMo study from @MDAndersonNews at the #ASCO22 prostate poster session. Always thankful for the wonderful mentorship from @aaparicioMD and the support from the @ConquerCancerFd Merit Award.